Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
It activates 1,942 genes (including 47 DNA repair genes and 14 antioxidant genes) and suppresses 762 genes involved in inflammation and fibrosis
Per serving: ~340 cal | 35g protein | 5g fiber
20 How results (e.g., weight loss, glycemic control, etc.) and tolerability (i.e., side effects) compare to current FDA-approved GLP1 and GLP1/GIP receptor agonists remain to be seen
Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
Both sermorelin and ipamorelin are fully synthetic peptides produced in laboratory settings
Yabut, J
